Drug Research

Clinical Studies of Natural Antiviral Gene-Eden-VIR/Novirin Are Listed on PubMed, the Most Selective and Prestigious Database of Medical Studies

October 16, 2017

SARASOTA, Fla., Oct. 16, 2017 /PRNewswire/ — Many people currently use herbal treatments to improve their health. However, some are still reluctant to use those treatments. To discover why, a study asked 601 individuals about their perceptions of natural treatments. [1] The analysis of the answers revealed that many doubted their efficacy. The study also […]

Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

October 16, 2017

NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced new positive preclinical data on OV101 that shows normalization of behavioral abnormalities that resemble those seen in people with Fragile X syndrome. The improvements seen with OV101, a […]

Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical Non-Invasive Electroceutical Significantly Increased Cardiac Function and Reduced Ventricular Remodeling in Infarcted Animals

October 13, 2017

LOS ANGELES, CA–(Marketwired – Oct 13, 2017) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today reported that it has completed a study to evaluate the potential efficacy of its Immunotronics™ platform, a non-invasive electroceutical, in a well-established preclinical […]

Ci Therapeutics Announces Positive Preclinical Data on ican.sleep Advanced Cannabinoid Formula; Anti-Insomnia Product Launch Expected in 2018

October 11, 2017

New York and Jerusalem, Israel, October 10, 2017…Ci Therapeutics (CIT), a CannRx/CAN:Israel-Cannabis joint venture, is proud to announce positive breakthrough pre-clinical data on its ican.sleep program utilizing the patented CannTrap cannabis reactor platform developed by CannRx.   ican.sleep is the first Cannaceutical (GMP, pharmaceutical grade cannabis product) planned to be available to the tens of […]

Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology

October 11, 2017

TORONTO, ONTARIO–(Marketwired – Oct. 11, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced positive initial results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid […]

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells

October 10, 2017

BRONX, N.Y., Oct. 9, 2017 /PRNewswire-USNewswire/ — Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for […]

Sirnaomics Publishes Results Showing Dual Targeting of TGF-β1 and COX-2 Reduces Human Skin Hypertrophic Scar through Activation of Fibroblast Apoptosis

October 9, 2017

GAITHERSBURG, Md., Oct. 6, 2017 /PRNewswire/ — Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has published results of research obtained with its research and clinical collaborator – Shanghai 9th People’s Hospital, China. The manuscript is titled “Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through […]

Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy

October 9, 2017

LA JOLLA, Calif., Oct. 6, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), in a poster presentation at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa, provided data which support the peripheral intravenous (IV) administration method the company plans to use in HOPE-2, its planned next clinical trial of its lead […]

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

October 9, 2017

Leuven, Belgium, 9th October 2017 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today announced that preclinical data on its THR-317 have been published in Experimental Eye Research. Experimental Eye Research peer-reviewed ThromboGenics’ pre-clinical studies designed to investigate inhibition of placental […]

Digitizing Clinical Research Processes – The New Frontier

October 6, 2017

One in three people will be diagnosed with cancer in their lifetime, but according to the NIH, only 3-5% of adult cancer patients participate in clinical trials. Advancing therapies in oncology and other disease areas is at the forefront of academic and commercial R&D. But enrollment and site initiation is often hindered by daunting, time […]

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

October 6, 2017

NEW YORK, Oct. 06, 2017 (GLOBE NEWSWIRE) — Motif Bio plc (“Motif Bio” or the “Company”) (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that new pre-clinical data with its investigational drug candidate iclaprim were presented today during the IDWeek 2017™ conference, held in San Diego, CA, 4-8 October 2017. […]

Chugai’s Bispecific Antibody “ERY974” Results of Preclinical Study Published in Science Translational Medicine

October 5, 2017

TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase I clinical study for solid tumors, were published in the online edition of Science Translational Medicine on October […]

OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment

October 3, 2017

NANTES, France, Oct. 02, 2017 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) presented new ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells. The data were presented at the 15th Annual Discovery on Target Conference which took place September 25-29, 2017 in […]

EnBiotix Reports Publication Highlighting Anti-persister Agent Targeting Antibiotic-Tolerant Infections in Antimicrobial Agents and Chemotherapy

October 3, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, announced today a publication in Antimicrobial Agents & Chemotherapy , a journal of the American Society for Microbiology, detailing data on EBX-001, the Company’s lead product for the treatment of […]

Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference

October 2, 2017

NEWTON, Mass.–(BUSINESS WIRE)–Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it presented new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs) at Cambridge Healthtech Institute’s Inaugural Targeting Tumor Myeloid Cells Conference, held September 27-28, 2017 in Boston. Siamab’s data show that […]

AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa

October 2, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced the publication of preclinical data demonstrating the activity of AB-PA01 in reducing biofilms. The paper, titled “Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis […]

Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy

October 2, 2017

HOPKINTON, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that it will present a poster (#A25) at 5:30 p.m. to 7:30 p.m. today, October 2, 2017, entitled “Pharmacodynamic and preclinical studies of […]

Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer

October 2, 2017

SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) — Atossa Genetics (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today a new program using Chimeric Antigen Receptor Therapy, or CAR-T. Atossa plans to use its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts […]

Focus on practical applications is stifling innovation, say 80% of surveyed chemistry professionals

September 27, 2017

Survey also shows a majority believe that expertise in working with digital tools is critical to career advancement  Chemistry is suffering due to its reputation for not being as innovative as other sciences, such as biology and physics, according to a survey of 186 industry professionals, carried out by Elsevier’s Reaxys team. 78% of chemists […]

Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society

September 26, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA conjugate platform at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 24 – 27, 2017 in Bordeaux, France.   ESC+ GalNAc […]

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

September 26, 2017

CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today presented the full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose, intravenous administration using its proprietary […]

Quanticate reinforces global offering with new Indian office

September 26, 2017

Quanticate, a global data-focused clinical research organisation (CRO), is further expanding its service offering into India with the opening of a new office. Strategically located in Bangalore, with access to the country’s extensive talent pool in the pharmaceutical services industry, the new office will be a base from which Quanticate will broaden its capabilities for […]

Sirona Biochem CEO’s Report on Progress

September 21, 2017

VANCOUVER, BC–(Marketwired – September 21, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to provide a corporate update. Dear Shareholders, I would like to thank you for your continued support while we work through the negotiations for our skin lightener. The following is an update on our progress to date. Skin […]

Sanofi and NIH researchers develop “three-in-one” antibodies as a potential breakthrough intervention for HIV/AIDS

September 21, 2017

CAMBRIDGE, Mass., Sept. 20, 2017 /PRNewswire/ — In a landmark study published in the journal Science today, researchers produced genetically engineered antibodies with the highest activity and breadth of coverage yet seen against human immunodeficiency virus (HIV-1).   Natural antibodies recognize a single target on a foreign protein. In this study, antibodies were engineered to […]

FLX Bio Selects Immuno-Oncology Clinical Candidate

September 21, 2017

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system, today announced the selection of FLX475 as its first immuno-oncology clinical candidate for the treatment of cancer. FLX475 is a best-in-class, oral, small molecule antagonist of CCR4. By blocking CCR4, […]

Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies

September 21, 2017

PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from a pneumonia-causing bacteria in preclinical studies.   Dr. J. Joseph Kim, […]

OncoQR ML’s Vaccine Platform Closes the Final Gap in the Immunological Attack Against Cancer

September 21, 2017

Vienna, Austria September 21, 2017 / B3C newswire / — OncoQR ML GmbH announced today that even a single therapeutic vaccine based on its proprietary S-TIR™ platform technology, is able to induce the killing of tumor target expressing cells by simultaneously activating all possible immunological pathways (humoral and cellular).   Scientific Breakthrough   By showing […]

FEEDBACK